[
  {
    "ts": "2025-10-19T12:45:00+00:00",
    "headline": "Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial",
    "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2025--Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered paper session (LBA42) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.",
    "url": "https://finance.yahoo.com/news/raludotatug-deruxtecan-demonstrated-clinically-meaningful-124500963.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "80f08942-a595-3684-884b-98003ae58bec",
      "content": {
        "id": "80f08942-a595-3684-884b-98003ae58bec",
        "contentType": "STORY",
        "title": "Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial",
        "description": "",
        "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2025--Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered paper session (LBA42) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.",
        "pubDate": "2025-10-19T12:45:00Z",
        "displayTime": "2025-10-19T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/d8ab4a1d31c02faa211f0f997b59061a",
          "originalWidth": 10600,
          "originalHeight": 1888,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eNDaMPFLLiTBWoydmhGzGg--~B/aD0xODg4O3c9MTA2MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d8ab4a1d31c02faa211f0f997b59061a.cf.webp",
              "width": 10600,
              "height": 1888,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V4oK5lTTDFua9U8eNpN9KA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d8ab4a1d31c02faa211f0f997b59061a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/raludotatug-deruxtecan-demonstrated-clinically-meaningful-124500963.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/raludotatug-deruxtecan-demonstrated-clinically-meaningful-124500963.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DSKYF"
            },
            {
              "symbol": "DSNKY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "4568.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]